Maltol

Summary

Maltol (CHEMBL31422) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including colorectal neoplasm and iron deficiency anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 126.11 Da · C6H6O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL31422
Name	Maltol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	8369
Molecular formula	C6H6O3
Molecular weight	126.11
InChIKey	XPCTZQVDEJYUGT-UHFFFAOYSA-N

SMILES: CC1=C(C(=O)C=CO1)O

IUPAC name: 3-hydroxy-2-methylpyran-4-one

Also known as: E-636, E636, FEMA NO. 2656, Ins no.636, Ins-636, Larixic acid, Maltol, NSC-2829, NSC-404458, Palatone, Veltol, SID11532903

Patent coverage: 8,480 distinct patent families (22,847 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.1	Potency	7943	nM	CHEMBL_ACT_3640536

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575
iron deficiency anemia	1	MONDO:0001356	HP:0001891

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	4
PHASE4	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05456932	PHASE4	UNKNOWN	Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT02680756	PHASE3	COMPLETED	Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
NCT02968368	PHASE3	COMPLETED	Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
NCT05126901	PHASE3	COMPLETED	Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
NCT05177484	PHASE3	COMPLETED	Perioperative Iron for Colorectal Cancer (PICoC Study)
NCT03181451	PHASE1	COMPLETED	Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
NCT05985070	Not specified	UNKNOWN	Evaluating the Effectiveness of Various Iron Salts in Oral Iron Therapy for Iron Deficiency and Anemia in Healthy Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).